Sana Biotechnology, INC Form 4 insider transactions

CEO Steve Harr reports acquisition and disposal of Sana Biotechnology stock and derivative securities, including stock options and restricted stock units.

Susan D. Wyrick, Acting CFO and Principal Accounting Officer of Sana Biotechnology, reports the vesting and subsequent tax withholding of restricted stock units.

FMR LLC, a significant shareholder of Sana Biotechnology, Inc., has sold a substantial number of common stock shares across multiple transactions on January 8, 2025.

Hans Edgar Bishop, a director at Sana Biotechnology, acquired 14,285 shares of common stock through fully vested restricted stock units.

Susan D. Wyrick, Acting Chief Financial Officer and Principal Accounting Officer of Sana Biotechnology, exercised stock options and disposed of shares to cover tax obligations on January 2, 2025.

Hans Edgar Bishop, a director at Sana Biotechnology, acquired 5,938 shares of common stock through vested restricted stock units on October 7, 2024.

Director Richard Mulligan of Sana Biotechnology sold 300,000 shares of common stock on September 24 and 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Patrick Yang, a director at Sana Biotechnology, files an amended Form 4 to correct the number of stock options acquired on June 6, 2024.

Richard Mulligan, a director at Sana Biotechnology, files an amended SEC Form 4 to correct the number of stock options acquired.

Robert Nelsen, a director and 10% owner of Sana Biotechnology, Inc., files an amended Form 4 to correct the number of option shares acquired on June 6, 2024.

Mary Agnes Wilderotter, a director at Sana Biotechnology, files an amended Form 4 to correct the number of option shares acquired.

Michelle Seitz, a director at Sana Biotechnology, files an amended Form 4 to correct the number of stock options acquired on June 6, 2024.

Alise Reicin, a director at Sana Biotechnology, files an amended Form 4 to correct the number of option shares acquired.

Douglas G. Cole, a director at Sana Biotechnology, files an amended Form 4/A to correct the number of option shares acquired on June 6, 2024.

Hans Edgar Bishop, a director at Sana Biotechnology, files an amended SEC Form 4 to correct the number of stock options acquired.

Joshua H. Bilenker, a director at Sana Biotechnology, files an amended Form 4/A to correct the number of option shares acquired on June 6, 2024.

Director Hans Edgar Bishop reported acquiring 4,911 shares of Sana Biotechnology common stock on July 5, 2024.

Director Richard Mulligan acquired stock options for 54,278 shares of Sana Biotechnology common stock on June 6, 2024.

Robert Nelsen, a director and 10% owner of Sana Biotechnology, acquired 54,278 stock options on June 6, 2024, exercisable at $7.36.

Director Mary Agnes Wilderotter acquired stock options for 54,278 shares of Sana Biotechnology, Inc. on June 6, 2024.

Director Michelle Seitz acquired stock options in Sana Biotechnology, Inc. on June 6, 2024.

Director Alise Reicin acquired stock options for 54,278 shares of Sana Biotechnology, Inc. at an exercise price of $7.36 on June 6, 2024.

Director Douglas G. Cole acquired stock options in Sana Biotechnology, Inc. exercisable for 54,278 shares of common stock.

Director Hans Edgar Bishop acquired stock options for 54,278 shares of Sana Biotechnology, Inc. on June 6, 2024.

Director Joshua H. Bilenker reports the acquisition of stock options in Sana Biotechnology, Inc.

Director Patrick Y. Yang reports acquisition of stock options in Sana Biotechnology.

Director Hans Edgar Bishop reports acquiring 2,774 shares of Sana Biotechnology common stock on April 5, 2024, bringing his total holdings to 5,779,640 shares.

Director Patrick Y. Yang of Sana Biotechnology, Inc. sold 25,000 shares of common stock at an average price of $9.452 on March 8, 2024.

Douglas E. Williams, EVP & President, R&D at Sana Biotechnology, reports the acquisition of stock options and restricted stock units.

Sana Biotechnology's CEO, Steve Harr, acquired 900,000 stock options and 200,000 restricted stock units on March 7, 2024, according to a Form 4 filing.